News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|August 31, 2023

Chapter 3. Pharmacokinetic Profiles of Long-Acting Stimulants

Sponsored by: Ironshore Pharmaceuticals

Episodes in this series

EP. 1 Chapter 1. History of Stimulants in ADHD

EP. 1 Chapter 1. History of Stimulants in ADHD

EP. 2 Chapter 2. Guidance and Recommendations for the use of Stimulants in Adults With ADHD

EP. 2 Chapter 2. Guidance and Recommendations for the use of Stimulants in Adults With ADHD

EP. 3 Chapter 3. Pharmacokinetic Profiles of Long-Acting Stimulants

EP. 3 Chapter 3. Pharmacokinetic Profiles of Long-Acting Stimulants

EP. 4 Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD

EP. 4 Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD

EP. 5 Chapter 5. Adult Perspectives on ADHD Medications

EP. 5 Chapter 5. Adult Perspectives on ADHD Medications

EP. 6 Chapter 6. Optimizing the Duration of Effect with Stimulant Medications

EP. 6 Chapter 6. Optimizing the Duration of Effect with Stimulant Medications

EP. 7 Chapter 7. Stimulant Prescribing Practices for Patients With ADHD

EP. 7 Chapter 7. Stimulant Prescribing Practices for Patients With ADHD

EP. 8 Chapter 8. Managing Patient Expectations During Treatment for ADHD

EP. 8 Chapter 8. Managing Patient Expectations During Treatment for ADHD

EP. 9 Appropriate Use of Stimulant Medications in Adults With ADHD

EP. 9 Appropriate Use of Stimulant Medications in Adults With ADHD

IP001858 08/23

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Chapter 8. Managing Patient Expectations During Treatment for ADHD

By

August 31st 2023

Chapter 7. Stimulant Prescribing Practices for Patients With ADHD

By

August 31st 2023

Chapter 6. Optimizing the Duration of Effect with Stimulant Medications

By

August 31st 2023

Chapter 5. Adult Perspectives on ADHD Medications

By

August 31st 2023

Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD

By

August 31st 2023

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD

Filling the Gap Between IV Ketamine Clinical Use and Evidence-Based Standards

Developments in Cannabis Withdrawal and Addiction Treatment

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

Podcast: How AI Can Help in Everyday Psychiatry. A Conversation With Roy Perlis, MD